DSM, CRUCELL & RECEPTA

[BIZ: Heerlen, November 5]
DSM Biologics, a business unit of DSM Pharmaceutical Products and Crucell NV, announced that they have signed a non-exclusive PER.C6® technology research licensing agreement with Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma to use the PER.C6® technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research. Financial details were not disclosed.
http://www.dsm.com/